Pharmaline knows that DR70 is off patent.
GCDx knows this, UNI knows this, Arima knows this, and CSTamdl knows this. Odd that some RXPC shareholders apparently still do not know this.
These entities are all working with DR70 without licensing it from, or paying any royalties or fees to, Radient Pharmaceuticals. This is why Radient Pharmaceuticals died and RXPC stock is now worthless. If this is still not clear, let's list Radient's "assets" and what happened to those assets:
-> DR-70: Transferred to AMDL, Inc. and now off patent, so several entities around the globe are currently trying to test/manufacture/market it.
-> CIT: declared worthless and transferred to NuVax.
-> Jade Holdings: revealed to be worthless.
-> Publications and research: CST in Hong Kong, led by Radient CEO and Officers Charter and Brown, now claims these assets as their own.
What does Radient Pharmaceuticals have left? Nothing. Well, not assets anyway. They have 5 billion shares issued and they have about $20 million in debt and they have 2.5 years of missing SEC financial filings, but those are reasons NOT to merge with Radient, and we are trying to find reasons why Arima or Provista or ANYONE would want to merge with Radient.
